Eurofins Scientific SE Stock
Stocks
ERF
FR0014000MR3
Biotechnology & Medical Research
OTC Markets Traded|
Market Closed -
Euronext Paris
11:55:00 2026-11-06 am EST
|
5-day change | 1st Jan Change | ||
| 88.64 EUR | -0.45% |
|
+1.05% | +42.05% |
| Oct. 26 | Eurofins Scientific, Heading for a Sixth Consecutive Gain |  |
| Oct. 22 | Eurofins Reportedly Tests Market for Eag Laboratories | CI |
| Market Cap | 15.39B 17.16B 14.06B 12.84B 24.19B 1,613B 24.95B 170B 67.59B 861B 64.4B 63.02B 2,717B | P/E 2026 * |
29x | P/E 2027 * | 23x |
|---|---|---|---|---|---|
| Enterprise Value | 18.82B 20.98B 17.2B 15.7B 29.58B 1,972B 30.51B 207B 82.65B 1,052B 78.74B 77.06B 3,322B | EV / Sales 2026 * |
2.49x | EV / Sales 2027 * | 2.3x |
| Free-Float |
60.34% | Yield 2026 * |
0.9% | Yield 2027 * | 1.03% |
| Markets | Quality | ||
|---|---|---|---|
Euronext Paris
| ERF | Real-time | |
CBOE
| Real-time | ||
|
London S.E.
| 0MV5 | Delayed | |
|
Tradegate
| ESF0 | Real-time | |
|
Börse Stuttgart
| ESF0 | Delayed | |
|
OTC Markets
| ERFSF | Delayed | |
|
Xetra
| ESF0 | Delayed | |
|
CBOE
| 0MV5 | Real-time | |
|
Boerse Muenchen
| ESF0 | Real-time | |
|
Deutsche Boerse AG
| ESF0 | Delayed | |
|
Wiener Boerse
| ESF | End-of-day quote | |
|
Borsa Italiana
| 4ERF | End-of-day quote |
Last Transcript: Eurofins Scientific SE
| 1 day | -0.45% | ||
| 1 week | +1.05% | ||
| Current month | +1.05% | ||
| 1 month | +16.42% | ||
| 3 months | +26.85% | ||
| 6 months | +47.73% | ||
| Current year | +42.05% |
| 1 week | 85.52 |  | 89.28 |
| 1 month | 75.7 | | 89.28 |
| Current year | 56.84 | | 89.28 |
| 1 year | 54.86 | | 89.28 |
| 3 years | 39.47 | | 89.28 |
| 5 years | 39.47 | | 118.12 |
| 10 years | 29.82 | | 127.68 |
| Manager | Title | Age | Since |
|---|---|---|---|
Gilles Martin
CEO | Chief Executive Officer | 63 | 1986-12-31 |
Laurent Lebras
DFI | Director of Finance/CFO | - | 2014-12-31 |
Christian Wurst
PRN | Corporate Officer/Principal | 54 | 2019-09-30 |
| Director | Title | Age | Since |
|---|---|---|---|
Gilles Martin
CHM | Chairman | 63 | 1986-12-31 |
Yves-Loïc Martin
BRD | Director/Board Member | 60 | 2014-12-31 |
Valérie Hanote
BRD | Director/Board Member | 60 | 1989-12-31 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | Importance |
|---|---|---|---|---|---|---|
| 4/27/26 | Buy | 700 | 0.0004% | |||
| 4/19/26 | Sell | Chief Financial Officer | 3,000 | 0.0016% | ||
| 4/19/26 | Exercice | Executive/Senior Manager | 700 | 0.0004% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -0.45% | +1.05% | +51.21% | +74.63% | 17.16B | |
| -4.83% | +3.51% | +53.62% | +61.75% | 65.94B | |
| -1.34% | +2.98% | +24.79% | +100.18% | 56.53B | |
| +0.02% | +1.07% | +10.63% | +76.66% | 56.88B | |
| +5.09% | +9.89% | +22.45% | +107.48% | 46.49B | |
| +2.62% | +1.68% | +28.91% | +37.01% | 44.8B | |
| +8.24% | +0.51% | +213.26% | +792.66% | 41.59B | |
| -1.86% | +10.13% | +26.82% | +53.22% | 35.35B | |
| -2.97% | -9.84% | +88.86% | +76.17% | 33.29B | |
| -2.18% | +7.06% | +36.06% | -4.95% | 24.92B | |
| Average | +0.23% | +3.03% | +55.66% | +137.48% | 42.29B | |
| Weighted average by Cap. | +0.18% | +3.31% | +53.04% | +140.18% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 7.57B 8.44B 6.92B 6.31B 11.89B 793B 12.27B 83.36B 33.24B 423B 31.67B 30.99B 1,336B | 8.02B 8.94B 7.33B 6.69B 12.61B 841B 13.01B 88.37B 35.24B 449B 33.57B 32.85B 1,416B |
| Net income | 547M 610M 500M 456M 860M 57.33B 887M 6.03B 2.4B 30.59B 2.29B 2.24B 96.57B | 675M 753M 617M 563M 1.06B 70.78B 1.09B 7.44B 2.97B 37.77B 2.83B 2.77B 119B |
| Net Debt | 3.43B 3.82B 3.13B 2.86B 5.39B 359B 5.56B 37.76B 15.06B 192B 14.35B 14.04B 605B | 3.08B 3.43B 2.81B 2.57B 4.84B 323B 4.99B 33.91B 13.52B 172B 12.88B 12.61B 543B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 26-11-06 | €88.64 | -0.45% | 326,537 |
| 26-11-05 | €89.04 | +1.16% | 265,720 |
| 26-11-04 | €88.02 | +0.89% | 373,855 |
| 26-11-03 | €87.24 | -0.89% | 319,688 |
| 26-11-02 | €88.02 | +0.34% | 248,845 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- ERF Stock
Select your edition
All financial news and data tailored to specific country editions
